WO2018082964A1 - Procédé de production de pyridazinyle-amides dans une synthèse one pot - Google Patents

Procédé de production de pyridazinyle-amides dans une synthèse one pot Download PDF

Info

Publication number
WO2018082964A1
WO2018082964A1 PCT/EP2017/077091 EP2017077091W WO2018082964A1 WO 2018082964 A1 WO2018082964 A1 WO 2018082964A1 EP 2017077091 W EP2017077091 W EP 2017077091W WO 2018082964 A1 WO2018082964 A1 WO 2018082964A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
compounds
reaction
cio
phenyl
Prior art date
Application number
PCT/EP2017/077091
Other languages
English (en)
Inventor
Birgit GOCKEL
Roland Goetz
Jochen Dietz
Sebastian Soergel
Eric KLAUBER
Joachim Gebhardt
Original Assignee
Basf Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Se filed Critical Basf Se
Publication of WO2018082964A1 publication Critical patent/WO2018082964A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms

Definitions

  • the invention relates to a process A for the preparation of compounds I
  • R 2 H halogen, CN, or N0 2 ;
  • Ci-Cio-alkyl C 2 -Cio-alkenyl, or C 2 -Cio-alkynyl, which are unsubstituted, halogen- ated, or substituted with R x ;
  • heterocyclyl hetaryl, C3-Cio-cycloalkyl, C3-Cio-cycloalkenyl, or phenyl, which are unsubstituted, or substituted with R y , or R x ;
  • R 3 H halogen, CN, N0 2 ;
  • Ci-Cio-alkyl C 2 -Cio-alkenyl, or C 2 -Cio-alkynyl, which are unsubstituted, halogen- ated, or substituted with R x ;
  • heterocyclyl hetaryl, C3-Cio-cycloalkyl, C3-Cio-cycloalkenyl or phenyl, which are unsubstituted, or substituted with R y , or R x ;
  • Ci-Cio-alkyl C 2 -Cio-alkenyl, or C 2 -Cio-alkynyl, which are unsubstituted, halogen- ated, or substituted with R x ;
  • heterocyclyl heterocyclyl, heterocyclyl-Ci-C4-alkyl, phenyl, hetaryl, phenyl-Ci-C4-alkyl, hetaryl-Ci-C4-alkyl, in which groups the ring is unsubstituted, or substituted with halogen, CN, NO2, Ci-C4-alkyl, Ci-C4-haloalkyl, Ci-C4-alkoxy, orCi-C4- haloalkoxy;
  • Ci-C4-alkyl Ci-C4-haloalkyl, C3-C6-cycloalkyl, C3-C6-cycloalkylmethyl, C3- C6-halocycloalkyl, C2-C4-alkenyl, C2-C4-haloalkenyl, C2-C4-alkynyl, C1-C4- alkoxy-Ci-C4-alkyl; or
  • heterocyclyl heterocyclyl, heterocyclyl-Ci-C4-alkyl, phenyl, hetaryl, phenyl-Ci-C4-alkyl, and hetaryl-Ci-C4-alkyl, in which groups the ring is unsubstituted, or substituted with halogen, CN, NO2, Ci-C4-alkyl, Ci-C4-haloalkyl, Ci-C4-alkoxy, or Ci-C4-haloalkoxy;
  • R f independently H, Ci-C4-alkyl, Ci-C4-haloalkyl, C3-C6-cycloalkyl, C3-C6- cycloalkylmethyl, C3-C6-halocycloalkyl, C2-C4-alkenyl, C2-C4-haloalkenyl, C2-C4-alkynyl, Ci-C4-alkoxy-Ci-C4-alkyl, Ci-C4-alkylcarbonyl, Ci-C4-halo- alkylcarbonyl, Ci-C4-alkylsulfonyl, Ci-C4-haloalkylsulfonyl;
  • heterocyclyl heterocyclyl-Ci-C4-alkyl, heterocyclylcarbonyl, heterocyclyl- sulfonyl, phenyl, phenylcarbonyl, phenylsulfonyl, hetaryl, hetarylcarbonyl, hetarylsulfonyl, phenyl-Ci-C4-alkyl, and hetaryl-Ci-C4-alkyl, in which groups the ring is unsubstituted, or substituted with halogen, CN, NO2, Ci-C4-alkyl, Ci-C4-haloalkyl, Ci-C4-alkoxy, and Ci-C4-haloalkoxy; or
  • R e and R f are together with the nitrogen atom to which they are bound form a 5- or 6-membered, saturated, or unsaturated heterocycle, in which heter- ocycle none, or one ring member atom is replaced by O, S or N, and wherein the heterocycle is unsubstituted or substituted with halogen, CN, NO2, Ci-C4-alkyl, Ci-C4-haloalkyl, Ci-C4-alkoxy, or Ci-C4-haloalkoxy;
  • R h independently H, Ci-C4-alkyl, Ci-C4-haloalkyl, C3-C6-cycloalkyl, C3-C6- halocycloalkyl, C2-C4-alkenyl, C2-C4-haloalkenyl, C2-C4-alkynyl, Ci-C4-alk- oxy-Ci-C4-alkyl;
  • heterocyclyl heterocyclyl, heterocyclyl-Ci-C4-alkyl, phenyl, hetaryl, phenyl-Ci-C4-alkyl, and hetaryl-Ci-C4-alkyl, in which groups the ring is unsubstituted, or substituted with halogen, CN, NO2, Ci-C4-alkyl, Ci-C4-haloalkyl, Ci-C4-alkoxy, or Ci-C4-haloalkoxy;
  • Ci-C4-alkyl Ci-C4-haloalkyl, C3-C6-cycloalkyl, C3-C6-cycloalkylmethyl, C3-C6-halocycloalkyl, C2-C4-alkenyl, C2-C4-haloalkenyl, C2-C4-alkynyl, Ci- C4-alkoxy-Ci-C4-alkyl; or
  • C3-C6-cycloalkyl 5- to 7-membered heterocyclyl, 5- or 6-membered hetaryl, phenyl, C3-C6-cycloalkoxy, 3- to 6-membered heterocyclyloxy, phenoxy, which are unsubstituted, or substituted with Ry;
  • n 0, 1 or 2;
  • X halogen N3, p-nitrophenoxy, (2,5-dioxopyrrolidin-1-yl)oxy, pentafluorophenoxy, OH, Ci-C6-alkoxy, C6-Cio-aryloxy, or C6-Cio-aryl-Ci-C6-alkoxy.
  • the invention further relates to compounds III in the form of their adduct salts with HCI.
  • These compounds are highly versatile precursors for the preparation of chemicals, such as compounds in the pharmaceutical and agrochemical field. They are particularly advantageous as intermediates for the preparation of compounds I because they are directly obtained by previous production steps and can be applied a such in Process A.
  • Compounds III, their salts, tautomers, or enantiomers are produced in Process B by reaction of (a) compounds IVa, their salts, tautomers, or enantiomers, or (b) compounds IVb, their salts, tautomers, or enantiomers, or of a mixture of (a) and (b)
  • HCI scavenger as a further chemical substance
  • H2O is usually detrimental to the yield of further conversions of compounds III and must be removed in an additional process step, which translates into higher production costs.
  • Processes B of the above type have been disclosed in WO2016180833.
  • Process A is applied in the production of pesticidal compounds I that are particularly useful for combating invertebrate pests (cf. WO2010/034737, WO2010/034738, and
  • Process B is preferably carried out in the absence of an HCI scavenger, the produced HCI (typically 2 equivalents compared to the amount of compounds IVa and IVb) is usually at least partially still present in the crude reaction product, when the hydrogenation catalyst is removed. Due to the basic functionalities of compounds III, they are then at least partially present in the crude reaction product in form of their adduct salts with HCI. It has been discovered that it is advantageous to carry out Process A and Process B as a one-pot process without intermediate isolation of compounds III.
  • the one-pot process has the advantages of fewer manufacturing steps, reduced costs, specifically, solid handling steps, less equipment, shorter batch times, and higher yields.
  • (a) compounds IVa, salts, tautomers, or enantiomers thereof, or (b) compounds IVb, salts, tautomers, or enantiomers thereof, or mixtures of (a) and (b) are produced via the following reaction sequence by reaction of compounds V with POC to yield 3,4,5-trichloropyridazine, and subsequent reaction with R 1 -NH2 either as a one- pot process (Process C); or by reaction of 3,4,5-trichloropyridazine with R 1 -NH2, wherein optionally the 3,4,5-trichloropyridazine is produced by reaction of compounds V with POCI3 (Process D).
  • Compounds V may in turn be produced by reaction of mucochloric acid with hydrazine (N2H4) (Process E).
  • reaction of compounds V with POCI3 and R 1 -NH2 can be carried out via isolation of 3,4,5-trichloropyridazine, or via a one-pot reaction without the isolation of 3,4,5-trichloropyridazine.
  • dichloropyridazine amine compounds are prepared starting from 3,4,5-trichloropyridazine by means of a nucleophilic substitution reaction with an amine compound.
  • WO201 1/038572 describes the preparation of a mixture of 3,5- dichloro-4-pyridazineamine and 5,6-dichloro-4-pyridazineamine by reacting 3,4,5-trichloropyridazine with ammonia gas for a reaction time of 4 days.
  • the same reaction is also described in US4,728,355, wherein the reaction is performed in a sealed tube at a temperature of 120-130 °C for five days.
  • WO2012/098387 discloses the reaction of 3,4,5-trichloropyridazine with 2-methylaminoethanol as nucleophile. Although a secondary amine, which is more nucleophilic than a primary amine is used as a nucleophile, the reaction is not quantitative, and a laborious work-up by column chromatography is required. Donna L. Romero et al. (Journal of Medicinal Chemistry, 1996, Vol. 39, No. 19, pp.
  • W096/18628 discloses the same reaction, wherein 3,4,5-trichloropyridazine and isopropylamine are refluxed in toluene for three hours. Column chromatography is required afterwards to isolate the desired compound 4-isopropylamino-3,5-dichloropyri- dazine.
  • the processes for the preparation of dichloropyridazine amines as described in the prior art are either disadvantageous in terms of the reaction conditions, the yields, and/or the work-up requirements.
  • it is another disadvantage of the processes described in the art that the irritant compound 3,4,5-trichloropyridazine has to be prepared and handled as a starting material. Solid handling of 3,4,5- trichloropyridazine is particularly disadvantageous on commercial scale.
  • Substituents R 1 being CH3CH2 are equally of particular interest because these can be advantageously applied in the preparation of compounds I, as described above.
  • the object has been achieved by a one-pot Process C for preparing (a) compounds IVa or salts, tautomers, N-oxides, or (b) compounds IVb, or salts, tautomers, or N- oxides, or (c) a mixture of (a) and (b)
  • the process is more economic and suitable for upscaling.
  • very high yields of the dichloropyridazine amine compounds can be obtained by the above process, whereby the reaction of the in situ formed 3,4,5-trichloropyridazine with the amine compound R 1 -NH2 does not require harsh reaction conditions. Due to the high yields, a laborious work-up can also be avoided.
  • Process D for preparing (a) compounds IVa or salts, tautomers, N-oxides, or (b) compounds IVb, or salts, tauto- mers, or N-oxides, or (c) a mixture of a) and (b)
  • Ch CI-bNI-b in Process C or Process D is particularly advantageous to use Ch CI-bNI-b in Process C or Process D as a nucleophile in the substitution reaction.
  • prior art suggests harsh reaction conditions or at least very long reaction times for the nucleo- philic substitution reaction, it has been found that moderate reaction conditions with reaction temperatures of, e.g., not more than 100°C and reaction times of not more than 12 hours suffice to provide the desired dichloropyridazine ethylamines with high yields, and without having to perform a laborious work-up.
  • halogen denotes in each case F, Br, CI, or I, especially F, CI, or Br, and in particular CI.
  • alkyl as used herein and in the alkyl moieties of al- kylamino, alkylcarbonyl, alkylthio, alkylsulfinyl, alkylsulfonyl and alkoxyalkyl denotes in each case a straight-chain or branched alkyl group having usually from 1 to 10 carbon atoms, frequently from 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, more preferably from 1 to 3 carbon atoms.
  • alkyl group examples include CH3, CH3CH2, CH3CH2CH2, (CH 3 ) 2 CH, CH3CH2CH2CH2, CH3CH2CH(CH3), (CH 3 ) 2 CHCH 2 , (CH 3 ) 3 C, n-pentyl, 1 -methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1 -ethylpropyl, n-hexyl, 1 , 1 -dimethylpropyl, 1 ,2-dimethylpropyl, 1 -methylpentyl, 2-methylpentyl, 3- methylpentyl, 4-methylpentyl, 1 , 1 -dimethylbutyl, 1 ,2-dimethylbutyl, 1 ,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1 -ethylbutyl, 2-ethyl
  • haloalkyl as used herein and in the haloalkyl moieties of haloalkyl- carbonyl, haloalkoxycarbonyl, haloalkylthio, haloalkylsulfonyl, haloalkylsulfinyl, haloal- koxy and haloalkoxyalkyl, denotes in each case a straight-chain or branched alkyl group having usually from 1 to 10 carbon atoms, frequently from 1 to 6 carbon atoms, preferably from 1 to 4 carbon atoms, wherein the hydrogen atoms of this group are partially or totally replaced with halogen atoms.
  • haloalkyl moieties are select- ed from Ci-C4-haloalkyl, more preferably from Ci-C 3 -haloalkyl or Ci-C2-haloalkyl, in particular from Ci-C 2 -fluoroalkyl such as CH 2 F, CHF 2 , CF 3 , CHFCH 3 , CH 2 CH 2 F, CH2CHF2, CH2CF 3 , CF2CF 3 , and the like.
  • alkoxy denotes in each case a straight-chain or branched alkyl group which is bonded via an oxygen atom and has usually from 1 to 10 carbon atoms, frequently from 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms.
  • alkoxy group examples include CH 3 0, CH 3 CH20, CH 3 CH 2 CH 2 0, (CH 3 ) 2 CHO, CH 3 CH2CH 2 CH 2 0, CH3CH2C(CH3)0, (CH 3 ) 2 CHCH 2 0, (CH 3 ) 3 C, and the like.
  • alkoxyalkyl refers to alkyl usually comprising 1 to 10, frequently 1 to 4, preferably 1 to 2 carbon atoms, wherein 1 carbon atom carries an alkoxy radical usually comprising 1 to 4, preferably 1 or 2 carbon at- oms as defined above.
  • haloalkoxy denotes in each case a straight-chain or branched alkoxy group having from 1 to 10 carbon atoms, frequently from 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, wherein the hydrogen atoms of this group are partially or totally replaced with halogen atoms, in particular F-atoms.
  • Ci-C4-haloalkoxy in particular Ci-C2-fluoroalk- oxy, such as CH 2 FO, CHF 2 0, CF 3 0, CH 3 CHFO, CH 2 FCH 2 0, CHF 2 CH 2 0, CF 3 CH 2 0, CHCIFCH2O, CCIF2CH2O, CCI2FCH2O, CCI 3 CH 2 0, CF 3 CF 2 0 and the like.
  • haloalkylsulfonyl refers to an alkylsulfonyl group as mentioned above wherein the hydrogen atoms are substituted with F, CI, Br, or I.
  • haloalkylcarbonyl refers to an alkylcarbonyl group as mentioned above, wherein the hydrogen atoms are substituted with F, CI, Br, or I .
  • alkoxycarbonyl refers to an alkylcarbonyl group as defined above, which is bonded via an oxygen atom to the remainder of the molecule.
  • haloalkoxycarbonyl refers to an alkoxycarbonyl group as mentioned above, wherein the hydrogen atoms are substituted with F, CI, Br or I .
  • alkenyl denotes in each case a singly unsaturated hydrocarbon radical having usually 2 to 10, frequently 2 to 6, preferably 2 to 4 carbon atoms, e.g. vinyl, allyl (2-propen-1 -yl), 1 - propen-1 -yl, 2-propen-2-yl, methallyl (2-methylprop-2-en-1 -yl), 2-buten-1 -yl, 3-buten-1 - yl, 2-penten-1 -yl, 3-penten-1 -yl, 4-penten-1 -yl, 1 -methyl but-2-en-1 -yl, 2-ethylprop-2-en-en-
  • haloalkenyl refers to an alkenyl group as defined above, wherein the hydrogen atoms are partially or totally replaced with halogen atoms.
  • alkynyl denotes in each case a singly unsaturat- ed hydrocarbon radical having usually 2 to 10, frequently 2 to 6, preferably 2 to 4 carbon atoms, e.g.
  • haloalkynyl refers to an alkynyl group as defined above, wherein the hydrogen atoms are partially or totally replaced with halogen atoms.
  • cycloalkyl as used herein and in the cycloalkyl moieties of cycloalkoxy and cycloalkylthio denotes in each case a monocyclic cycloaliphatic radical having usually from 3 to 10 or from 3 to 6 carbon atoms, such as cyclopropyl (CC3H4), cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cy- clononyl and cyclodecyl or cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • cC3H z means cyclopropyl to which a number of z hydrogen atoms are bound.
  • halocycloalkyl as used herein and in the halocycloalkyl moieties of halocycloalkoxy and halocycloalkylthio denotes in each case a monocyclic cycloaliphatic radical having usually from 3 to 10 C atoms or 3 to 6 C atoms, wherein at least one, e.g. 1 , 2, 3, 4, or 5 of the hydrogen atoms, are replaced by halogen, in particular by fluorine or chlorine.
  • Examples are 1 - and 2- fluorocyclopropyl, 1 ,2-, 2,2- and 2,3-diflu- orocyclopropyl, 1 ,2,2-trifluorocyclopropyl, 2,2,3,3-tetrafluorocyclpropyl, 1 - and 2- chlorocyclopropyl, 1 ,2-, 2,2- and 2,3-dichlorocyclopropyl, 1 ,2,2-trichlorocyclopropyl, 2,2,3,3-tetrachlorocyclpropyl, 1 -,2- and 3-fluorocyclopentyl, 1 ,2-, 2,2-, 2,3-, 3,3-, 3,4-, 2,5-difluorocyclopentyl, 1 -,2- and 3-chlorocyclopentyl, 1 ,2-, 2,2-, 2,3-, 3,3-, 3,4-, 2,5-di- chlorocyclopentyl and the like.
  • cycloalkoxy refers to a cycloalkyl group as defined above, which is bonded via an oxygen atom to the remainder of the molecule.
  • cycloal- kenyl as used herein and in the cycloalkenyl moieties of cycloalkenyloxy and cycloal- kenylthio denotes in each case a monocyclic singly unsaturated non-aromatic radical having usually from 3 to 10, e.g. 3, or 4 or from 5 to 10 carbon atoms, preferably from
  • cycloalkenyl groups include cyclopropenyl, cyclohep- tenyl or cyclooctenyl.
  • halocycloalkenyl as used herein and in the halocyclo- alkenyl moieties of halocycloalkenyloxy and halocycloalkenylthio denotes in each case a monocyclic singly unsaturated non-aromatic radical having usually from 3 to 10, e.g. 3, or 4 or from 5 to 10 carbon atoms, preferably from 3- to 8 carbon atoms, wherein at least one, e.g.
  • carrier or “carbocyclyl” includes in general a 3- to 12- membered, preferably a 3- to 8-membered or a 5- to 8-membered, more preferably a 5- or 6-membered mono-cyclic, non-aromatic ring comprising 3 to 12, preferably 3 to 8 or 5 to 8, more preferably 5 or 6 carbon atoms.
  • the term “carbocycle” covers cycloalkyl and cycloalkenyl groups as defined above.
  • heterocycle or “heter- ocyclyl” includes in general 3- to 12-membered, preferably 3- to 8-membered or 5- to 8- membered, more preferably 5- or 6-membered, in particular 6-membered monocyclic heterocyclic non-aromatic radicals.
  • the heterocyclic non-aromatic radicals usually comprise 1 , 2, 3, 4, or 5, preferably 1 , 2 or 3 heteroatoms selected from N, O and S as ring members, where S-atoms as ring members may be present as S, SO or SO2.
  • heterocyclic radicals comprise saturated or unsaturated, non-aromatic heterocyclic rings, such as oxiranyl, oxetanyl, thietanyl, thietanyl-S-oxid (S-oxothietanyl), thietanyl-S-dioxid (S-dioxothiethanyl), pyrrolidinyl, pyrrolinyl, pyrazoli- nyl, tetrahydrofuranyl, dihydrofuranyl, 1 ,3-dioxolanyl, thiolanyl, S-oxothiolanyl, S-dioxo- thiolanyl, dihydrothienyl, S-oxodihydrothienyl, S-dioxodihydrothienyl, oxazolidinyl, oxa- zolinyl, thia
  • heterocyclic ring also comprising 1 or 2 carbonyl groups as ring members comprise pyrrolidin-2-onyl, pyrrolidin-2,5-dionyl, imidazolidin-2-onyl, oxazolidin-2-onyl, thiazolidin-2-onyl and the like.
  • heteroaryl includes monocyclic 5- or 6-membered heteroaromatic radicals comprising as ring members 1 , 2, 3, or 4 heteroatoms selected from N, O and S. Examples of 5- or 6-membered heteroaromatic radicals in- elude pyridyl, i.e. 2-, 3-, or 4-pyridyl, pyrimidinyl, i.e.
  • heteroaryl also includes bicyclic 8 to 10-membered heteroaromatic radicals com- prising as ring members 1 , 2 or 3 heteroatoms selected from N, O and S, wherein a 5- or 6-membered heteroaromatic ring is fused to a phenyl ring or to a 5- or 6-membered heteroaromatic radical.
  • Examples of a 5- or 6-membered heteroaromatic ring fused to a phenyl ring or to a 5- or 6-membered heteroaromatic radical include benzofuranyl, ben- zothienyl, indolyl, indazolyl, benzimidazolyl, benzoxathiazolyl, benzoxadiazolyl, benzo- thiadiazolyl, benzoxazinyl, chinolinyl, isochinolinyl, purinyl, 1 ,8-naphthyridyl, pteridyl, pyrido[3,2-d]pyrimidyl or pyridoimidazolyl and the like.
  • fused hetaryl radicals may be bonded to the remainder of the molecule via any ring atom of 5- or 6-mem- bered heteroaromatic ring or via a carbon atom of the fused phenyl moiety.
  • aryl includes mono-, bi- or tricyclic aromatic radicals having usually from 6 to 14, preferably 6, 10, or 14 carbon atoms.
  • Exemplary aryl groups include phenyl, naphthyl and anthracenyl. Phenyl is preferred as aryl group.
  • heterocyclyloxy refers to heterocyclyl, hetaryl, and phenyl, which are bonded via an oxygen atom to the remainder of the molecule.
  • heterocyclylsulfonyl refers to heterocyclyl, het- arylsulfonyl, and phenyl, respectively, which are bonded via the sulfur atom of a sulfonyl group to the remainder of the molecule.
  • alkylene refers to alkyl as defined above, which represents a linker between molecule and a substituent.
  • substituted refers in each case to a substitution by one, or more, same or different substituents.
  • halogenated refers to a partial, of complete substitution with halogen.
  • a sub-equivalent amount refers to one equivalent of a substance as compared to another. Accordingly, a sub-equivalent amount means less than one equivalent of a substance as compared to another, preferably 0.05 to 0.99 equivalents, more preferably 0.1 to 0.9 equivalents, most preferably 0.1 to 0.8 equivalents, and in particular 0.2 to 0.6 equiva- lents of a substance as compared to another.
  • an at least equivalent amount means at least one equivalent of a substance as compared to another, preferably at from 1 to 10 equivalents, more preferably from 1 to 5 equivalents, most preferably from 1 to 3 equivalents, and in particular from 1 to 2 equivalents.
  • pyridazine amine compound(s) refers to compounds III, i.e. pyridazine compounds with an amino group -NHR 1 as substituent in the 4-position of the pyridazine moiety. Thus, pyridazine amine compounds according to the invention do not comprise any further substituents at the pyridazine ring.
  • dichloropyridazine amine compound(s) covers compounds IVa or IVb, their salts, tautomers or combinations thereof, i.e.
  • pyridazine compounds with an amino group -NHR 1 as substituent and two chlorine substituents, wherein the substituents are present at those positions of the pyridazine moiety, which can be derived from formula IVa and IVb.
  • the terms "compounds” and “compounds of formula” have the same meaning and are thus interchangeably. They relate to compounds that are characterized by way of the respective structural formulae. Depending on the acidity or basicity as well as the reaction conditions, the compounds of the present invention may be present in the form of salts.
  • Such salts will typically be obtained by reacting the compound with an acid, if the compound has a basic functionality such as an amine, or by reacting the compounds with a base, if the compound has an acidic functionality such as a carboxylic acid group.
  • Cations, which stem from a base, with which the compounds of the present invention are reacted, are e.g.
  • alkali metal cations M a + alkaline earth metal cations M ea 2+ or ammonium cations NR 4 + , wherein the alkali metals are preferably sodium, potassium or lithium and the alkaline earth metal cations are preferably magnesium or calcium, and wherein the substituents R of the ammonium cation NR 4 + are preferably independently selected from H, Ci-Cio-alkyl, phenyl and phenyl-Ci-C2-alkyl.
  • Suitable cations are in particular the ions of the alkali metals, preferably lithium, sodium and potassium, of the alkaline earth metals, preferably calcium, magnesium and barium, and of the transition metals, preferably manganese, copper, zinc and iron, and also ammonium (NH 4 + ) and substi- tuted ammonium in which one to four of the hydrogen atoms are replaced by Ci-C 4 -al- kyl, Ci-C 4 -hydroxyalkyl, Ci-C 4 -alkoxy, Ci-C 4 -alkoxy-Ci-C 4 -alkyl, hydroxy-Ci-C 4 -alkoxy- Ci-C 4 -alkyl, phenyl or benzyl.
  • substituted ammonium ions comprise me- thylammonium, isopropylammonium, dimethylammonium, diisopropylammonium, trime- thylammonium, tetramethylammonium, tetraethylammonium, tetrabutylammonium, 2-hydroxyethylammonium, 2-(2-hydroxyethoxy)ethylammonium, bis(2-hydroxy- ethyl)ammonium, benzyltrimethylammonium and benzl-triethylammonium, furthermore phosphonium ions, sulfonium ions, preferably tri(Ci-C 4 -alkyl)sulfonium, and sulfoxoni- um ions, preferably tri(Ci-C 4 -alkyl)sulfoxonium.
  • Anions which stem from an acid, with which the compounds of the present invention have been reacted, are e.g. chloride, bromide, fluoride, hydrogensulfate, sulfate, dihydrogenphosphate, hydrogenphosphate, phosphate, nitrate, bicarbonate, carbonate, hexafluorosilicate, hexafluorophosphate, benzoate, and the anions of Ci-C 4 -alkanoic acids, preferably formate, acetate, propionate and butyrate.
  • Tautomers of the compounds of the present invention include keto- enol tautomers, imine-enamine tautomers, amide-imidic acid tautomers and the like.
  • N- oxide relates to a form of the compounds of the present invention in which at least one nitrogen atom is present in oxidized form (as NO).
  • N-oxides of the compounds of the present invention can only be obtained, if the compounds contain a nitrogen atom, which may be oxidized.
  • N-oxides may principally be prepared by standard methods, e.g. by the method described in Journal of Organometallic Chemistry 1989, 370, 17-31. However, it is preferred according to the invention that the compounds are not present in the form of N-oxides. On the other hand, under certain reaction conditions, it cannot be avoided that N-oxides are formed at least intermediary.
  • stereoisomers encompasses both optical isomers, such as enantiomers or diastereomers, the latter existing due to more than one centre of chirality in the molecule, as well as geometrical isomers (cis/trans isomers).
  • the compounds of the present invention may have one or more centres of chirality, in which case they may be present as mixtures of enantiomers or diastereomers.
  • the invention provides both the pure enantiomers or diastereomers and their mixtures. Suitable compounds of the invention also include all possible geometrical stereoisomers (cis/trans isomers) and mixtures thereof.
  • the compounds of the invention may be in the form of solids or liquids or in gaseous form.
  • the compounds may be amor- phous or may exist in one or more different crystalline states (polymorphs) which may have a different macroscopic properties such as stability or show different biological properties such as activities.
  • the present invention includes both amorphous and crystalline compounds, mixtures of different crystalline states, as well as amorphous or crystalline salts thereof.
  • one-pot refers to a set-up in which the product of a first reaction is used as educt in a subsequent second reaction without intermediate workup, preferably as a component of a composition further comprising the solvent of the first reaction.
  • the term “one-pot process” refers to a situation wherein no efforts for product isolation or purification are being made in between the reactions that are carried out in the one-pot process.
  • the term “one-pot” may refer to a set-up in which the first and the second reaction are carried out in one reaction vessel, or to a set-up in which the reaction vessel is exchanged after the first reaction and before the second reaction.
  • the term one-pot refers to a set-up in which the reaction vessel is exchanged after the first reaction and before the second reaction.
  • intermediate workup refers to a situation, wherein no isolation of reaction products is being carried out between the reaction steps, while exchange of solvents, or the addition of acids or bases between the reaction steps may optionally be carried out.
  • free base refers to organic molecules, e.g. compounds (III), containing an amine group, e.g. a primary, secondary, or tertiary amine group, but which are in the form of a salt, i.e. in the form of an adduct salt with an acid, such as HCI.
  • Process A is usually carried out by reaction of compounds II with compounds III
  • HX as a byproduct, wherein X has a meaning as defined for compounds II, preferably CI, in an amount of one equivalent compared to the amount of compounds I.
  • X is halogen, N3, p-nitrophenoxy, (2,5-dioxopyrrolidin-1 -yl)oxy, or pentafluorophenoxy, (i.e. the produced HX is an acid) preferably halogen, or in case compounds II are used in the form of their adduct salts with HCI, Process A is carried out in the presence of a base.
  • Compounds II, and compounds III are usually applied in equimolar amounts.
  • Process A is usually carried out at temperatures from -50 to 150 °C, preferably 0 to 150 °C, more preferably 0 to 120 °C, most preferably 10 to 100 °C, especially preferably 20 to 80, and in particular 20 to 50 °C.
  • the temperature is usually from 40 to 150 °C, prefera- bly 50 to 150 °C, and most preferably from 60 to 130 °C.
  • the temperature is usually from -20 to 60 °C, preferably 10 to 50 °C, most preferably 15 to 30 °C.
  • Suitable solvents for Process A are water; aliphatic hydrocarbons, preferably an aliphatic C5-Ci6-hydrocarbon, more preferably a C5-Ci6-alkane, or C5-Ci6-cycloalkane, such as pentane, hexane, cyclohexane, or petrol ether; aromatic hydrocarbons, preferably an aromatic C6-Cio-hydrocarbons, such as benzene, toluene, o-, m-, and p-xylene; halogenated hydrocarbons, preferably halogenated aliphatic Ci-C6-alkanes, or halogenated aromatic C6-Cio-hydrocarbons, such as CH2CI2, CHCI3, CCU, CH2CICH2CI, CCI3CH3, CHCI2CH2CI, CCI2CCI2, or chlorobenzene; alcohols, preferably Ci-C 4 -alco- hols and C 2 -
  • ethers preferably Ci-C 6 -cycloalkyl ethers, Ci-C 6 -alkyl-Ci-C 6 -alkyl ethers and Ci-C6-alkyl-C6-Cio-aryl ethers, such as CH3CH2OCH2CH3,
  • nitriles preferably Ci-C6-nitriles, such as CH3CN, and CH3CH2CN
  • ketones preferably Ci-C6-alkyl-Ci-C6-alkyl ketones, such as CH 3 C(0)CH 3 , CH 3 C(0)CH 2 CH 3 , CH3CH 2 C(0)CH 2 CH3, and CH 3 C(0)C(CH 3 ) 3 (MTBK)
  • amides and urea derivatives preferably dimethyl form amide (DMF), N-methyl-2- pyrrolidone (NMP), dimethyl acetamide (DMA), 1 ,3-dimethyl-2-imidazolidinone (DMI), 1 ,3-dimethyl-3,4,5,6-te
  • the solvent is an aliphatic hydrocarbon, aromatic hydrocarbon, halogenated hydrocarbon, ether, nitrile, amide, urea derivative, DMSO, or sulfolane.
  • the solvent is an aliphatic hydrocarbon.
  • the solvent is an aliphatic C5-Ci6-hydrocarbon.
  • the solvent is an aromatic hydrocarbon.
  • the solvent is an aromatic C6-C10- hydrocarbon.
  • the solvent is benzene, toluene, 0-, m-, or p- xylene.
  • the solvent is toluene.
  • the solvent is a halogenated hydrocarbon.
  • the solvent is a halogenated aliphatic Ci-C6-alkane. In another embodiment, the solvent is CH2CI2. In another embodiment, the solvent is a halogenated aromatic C6-Cio-hydrocarbon. In another embodiment, the solvent is an ether. In another embodiment, the solvent is a Ci- C6-cycloalkyl ether. In another embodiment, the solvent is a Ci-C6-alkyl-Ci-C6-alkyl ethers. In another embodiment, the solvent is a Ci-C6-alkyl-C6-Cio-aryl ether. In another embodiment, the solvent is an alcohol, preferably a Ci-C 4 -alcohol, more preferably CH3OH.
  • the solvent is an amide or urea derivative.
  • the solvent is DMF, NMP, DMA, DMI, DMPU, or HMPA.
  • the solvent is DMF.
  • the solvent is DMSO, or sul- folane.
  • Process A and Process B are carried out as a one-pot process, the solvent is usually exchanged after the termination of Process A and before the start of Process B.
  • Suitable bases are, in general, inorganic bases, such as alkali metal and alkaline earth metal hydroxides, such as LiOH, NaOH, KOH, and Ca(OH)2; alkali metal and alkaline earth metal oxides, such as U2O, Na20, CaO, and MgO; alkali metal and alkaline earth metal hydrides, such as LiH, NaH, KH and Cahb; alkali metal and alkaline earth metal carbonates, such as U2CO3, K2CO3 and CaCOs; alkali metal bicarbonates, such as NaHCOs; alkali and alkaline earth metal amides, such as UNH2, NaNhb, KNH2; organic bases, for example secondary amines, such as pyrrolidine; tertiary amines, such as diisopropylethylamine, (CH 3 )3N , (CH 3 CH 2 )3N , ((CH 3 )2CH) 3 N, N-methylpiperi-
  • Mixtures of the aforementioned bases are also possible, preferably a mixtures of organic and inorganic bases, more preferably a mixture of alkali or earth metal carbonates and amines, more preferably a mixture of alkali carbonates and tertiary amines, e.g. a mixture of K2CO3 and (CH3CH2)3N .
  • the ratio of the inorganic base to the organic base may be from 10:1 to 1 :10, preferably from 5:1 to 1 :5, more preferably from 2:1 to 1 :2, and in particular 1 .5:1 to 1 :1 .5.
  • the base is an organic base, preferably a secondary amine, a tertiary amine, substituted pyridine, polycyclic amides and amidines, or a mixture thereof.
  • the base is a secondary amine, a tertiary amine, or a mixture thereof.
  • the base is a tertiary amine, preferably (CH3CH2)3N .
  • the base may be added before the start of the reaction (i.e. to compounds III before addition of compounds II), during the reaction (i.e. after having admixed compounds II to compounds III), or after the reaction.
  • the combined amount of base in Process A and HCI scavenger in Process B is at least equivalent to the amount of produced acid (e.g. HCI) produced in both processes, preferably one to five equivalents, in particular one to two equivalents.
  • the amount of base in Process A is at least equivalent to the amount of acid (e.g. HCI) produced in both processes, preferably one to five equivalents, in particular one to two equivalents.
  • the amount of base added in Process A is at least equivalent to the amount of produced acid (e.g. HCI) in Process A, preferably one to five equivalents, in particular one to two equivalents.
  • the base may be added before, during, or after the addition of compounds II to compounds III, preferably it is added before the addition.
  • the whole amount of the base may be added in one step, or the amount may be split and admixed to the reaction mixture at several points of time.
  • the amount of the base is split and added before the reaction, and during the reaction.
  • the amount of the base is split and added before the reaction, and after the reaction.
  • the amount of the base is split and added during the reaction, and after the reaction.
  • the amount of the base is split and added before the reaction, and during the reaction.
  • compounds III are used in the form of the free amine as educts for Process A. Alternatively, they may be used in the form of their salts as educts for Process A. In one embodiment compounds III are used in the form of their adduct salt with HCI. Salts of compounds III also include mixtures of compounds III and their salts. Such mixtures may have a molar ratio of compounds III to their salts from 2:1 to 1 :1000, preferably 1 :1 to 1 :1000, more preferably 1 :2 to 1 :1000, most preferably 1 :2, 5 to 1 :1000. Usually the molar ratio of compounds III to their salts is at least 1 :1 , preferably at least 1 :2, and most preferably 1 :2.5.
  • Typical adduct salts of compounds III with HCI comprises one or two molecules of HCI per molecule of compounds III.
  • the adduct salt of compounds III with HCI comprises one molecule of HCI per molecule of compounds III.
  • the adduct salt of compounds III with HCI compris- es two molecules of HCI per molecule of compounds III.
  • Process B may be carried out by reaction of (a) compounds IVa, their salts, tauto- mers, or enantiomers, or (b) compounds IVb, their salts, tautomers, or enantiomers, or mixtures of (a) and (b)
  • Hydrogenation catalyst relates to heterogeneous and homogeneous hydrogenation catalysts, preferably heterogeneous catalysts. It is known in the art that Pt, Pd, Rh, and Ru form highly active catalysts. Non-precious metal catalysts, such as catalysts based on nickel (such as Raney nickel and Urushibara nickel) are economical alternatives. Preferred hydrogenation catalysts include Pt, Pd, Rh, Ru, Ni, or Co on carriers such as carbon. In a preferred embodiment, the hydrogenation catalyst is Pt or Pd on a carrier, Raney nickel, or Raney cobalt, and is preferably Pt or Pd on carbon. Optionally, the catalyst may be doped with sulfur or selenium. This can enhance the selectivity of the catalyst.
  • the hydrogenation catalyst is Pd or Pt on carbon, wherein the Pd- or Pt-content is preferably in the range of from 0.1 to 15 wt%, more preferably from 0.5 to 10 wt% based on the carbon. In another embodiment, the amount of Pd, or Pt is from 0.001 to 1 wt%, preferably from 0.01 to 0.1 wt% based on the starting material. In another embodiment, the hydrogenation catalyst is Pd on carbon, wherein the Pd- content is preferably in the range of from 0.1 to 15 wt%, more preferably from 0.5 to 10 wt% based on the carrier material.
  • the amount of Pd is from 0.001 to 1 wt%, preferably from 0.01 to 0.1 wt% based on the starting material.
  • 10wt% Pd/C is used in amount of 0.01 to 0.1 wt% based on the amount of the starting material.
  • the hydrogenation catalyst is Pt on carbon, wherein the Pt-content is preferably of from 0.1 to 15 wt%, more preferably from 0.5 to 10 wt% based on the carrier material.
  • the amount of Pt is from 0.001 to 1 wt%, preferably from 0.01 to 0.1 % based on the starting material. It is especially preferred that 10% Pt/C is used in amount of 0.01 to 0.1 wt% based on the amount of the starting material.
  • the catalyst is preferably used in the form of a powder.
  • the catalyst used on the carrier material carbon is Pt, or Pd. After a reaction cycle, the catalyst can be filtered off and reused without noticeable loss of activity.
  • Suitable solvents are H2O; aliphatic hydrocarbons, preferably an aliphatic C5-Ci6-hydrocarbon, more preferably a C5-C16- alkane, or C5-Ci6-cycloalkane, such as pentane, hexane, cyclohexane, or petrol ether; aromatic hydrocarbons, preferably an aromatic C6-Cio-hydrocarbons, such as benzene, toluene, 0-, m-, and p-xylene; alcohols, preferably Ci-C4-alcohols and C 2 -C 4 -alkane diols, such as CH 3 OH, CH3CH2OH, CH 3 CH 2 CH 2 OH, CH 3 CH(OH)CH 3 , CH 3 (CH 2 ) 3 OH, and C(CH 3 ) 3 OH, CH 2 (OH)CH 2 (OH), CH 3 CH(OH)CH 2 OH
  • esters preferably esters of aliphatic Ci-C6-alcohols with aliphatic Ci-C6-carboxylic acids, esters of aromatic C6-Cio-alcohols with aromatic C6-Cio-carboxylic acids, cyclic esters of (jo-hydroxy-Ci-C6-carboxylic acids, such as CH 3 C(0)OCH 2 CH 3 , CH 3 C(0)OCH 3 , CH 3 C(0)OCH 2 CH 2 CH 2 CH 3 ,
  • amides and urea derivatives preferably DMF, NMP, DMA, DMI, DMPU, and HMPA.
  • Preferred solvents are protic solvents, such as H 2 0, Ci-C 4 -alcohols, and C 2 -C 4 -alkane diols, preferably CHsOH , CH 3 CH 2 OH , CH 3 CH 2 CH 2 OH , CH 3 CH(OH)CH 3 , CH 3 (CH 2 ) 3 OH , and C(CH 3 ) 3 OH, more preferably CH 3 OH, and CH 3 CH 2 OH.
  • the solvent is CH3OH.
  • the solvent CH3CH2OH Mixtures of said solvents can also be used.
  • the solvent is exchanged after the termination of Process B for carrying out Process A.
  • the applied hb-pressure is in the range of from 0.1 to 10 bar, preferably in the range of from 0.1 to 1 bar, more preferably in the range of from 0.1 to 0.5 bar.
  • the applied hb-pressure is in the range of from 1 to 10 bar, preferably 2 to 8 bar, more preferably 5 to 7 bar.
  • Higher pressures in the range of from 0.6 bar to 10 bar, preferably 3 bar to 7 bar can be advantageous if the starting material contains impurities in an amount of more than 1 % by weight.
  • reaction temperature is kept within a range of from 20 to 100 °C, preferably in the range of from 30 to 80 °C.
  • the hydrogenation reaction is exothermic, it can be required to cool the reaction mixture afterwards to keep the temperature preferably below 70 °C.
  • a reaction temperature in the range of from 60 to 70 °C is particularly preferred.
  • reaction times may vary over a broad range. Preferred reaction times are in the range of from 1 hour to 12 hours, preferably in the range of from 6 hours to 12 hours, e.g. 9 or 10 hours.
  • HCI scavenger refers to a chemical substance, which is added to a reaction mixture to remove or de-activate HCI.
  • HCI scavengers include bases, buffers, and precursors of ionic liquids, i.e. compounds that bind protons.
  • HCI scavenger refers to a chemical substance, which is added to the reaction mixture, and does not include the starting materials of the reaction, i.e. the compounds IVa, or IVb.
  • the produced HCI is then still in the reaction mixture, when the hydrogenation catalyst is removed. Due to the basic functionalities of compounds III, they are in this case present after the reaction in form of their adduct salts with HCI.
  • the HCI scavenger may be added after the removal of the hydrogenation catalyst, preferably without the addition of H2O. It has been found that an HCI scavenger may advantageously be used after removal of the hydrogenation catalyst, so that the HCI is bound and not set free in gaseous form. In case an HCI scavenger is added after the removal of the hydrogenation catalyst, it may be added in an at least equivalent amount compared to the amount of produced HCI in the hydrogenation reaction, or in a sub-equivalent amount compared with the produced amount of HCI in the hydrogena- tion reaction.
  • the HCI scavenger is added after the removal of the hydrogenation catalyst in an at least equivalent amount compared with the produced amount of HCI in the hydrogenation reaction, e.g. at from 1 to 10 equivalents, preferably from 1 to 5, and most preferably from 1 to 3 equivalents of the HCI scavenger com- pared to the amount of HCI produced in Process B.
  • the HCI scavenger is added after the removal of the hydrogenation catalyst in a sub-equivalent amount compared with the amount of HCI in the reaction mixture, e.g. in a ratio of equivalents of HCI scavenger to equivalents HCI produced in Process B from 10:100 to 99:100, preferably 30:100 to 90:100, more prefera- bly from 50:100 to 70:100.
  • an HCI scavenger is neither used during the reaction, nor after the removal of the hydrogenation catalyst in Process B.
  • an HCI scavenger is added after removal of the hydrogenation catalyst in a sub- equivalent amount - compounds III remain in the form of their salts, usually in form of their adduct salts with HCI, and are directly used as such for Process A. Accordingly, the salts of compounds III are not converted, or not converted completely to compounds III by reaction with an HCI scavenger before Process A.
  • Compounds III are advantageously also not isolated prior to Process A, but remain in the mother liquor, preferably in the form of their adduct salts with HCI, more preferably as a composition comprising the HCI adduct salts of compounds III in CH3OH, CH3CH2OH, or a mixture thereof.
  • Typical HCI scavengers are bases, buffers, precursors of ionic liquids, and combinations thereof. As described above, it is advantageous to use no HCI scavenger for production of compounds III in Process B before the hydrogenation catalyst has been re- moved.
  • Typical bases that may be used as HCI scavengers include alkali metal and alkaline earth metal hydroxides, alkali metal and alkaline earth metal oxides, alkali metal and alkaline earth metal hydrides, alkali metal amides, alkali metal and alkaline earth metal carbonates, alkali metal bicarbonates, alkali metal alkyls, alkyl magnesium halides, alkali metal and alkaline earth metal alcoholates, and nitrogen containing bases including tertiary amines, pyridines, bicyclic amines, ammonia, and primary amines.
  • Typical Buffers include aqueous and non-aqueous buffers, and are preferably non-aqueous buffers.
  • Preferred buffers include buffers based on acetate or formate, e.g. sodium acetate or ammonium formate.
  • Precursors of ionic liquids include imidazoles.
  • the HCI scavenger is selected from the group consisting of bases including alkali metal and alkaline earth metal hydroxides, alkali metal and alkaline earth metal oxides, alkali metal and alkaline earth metal hydrides, alkali metal amides, alkali metal and alkaline earth metal carbonates, alkali metal bicarbonates, alkali metal alkyls, alkylmagnesium halides, alkali metal and alkaline earth metal alcoholates, nitro- gen containing bases including tertiary amines, pyridines, bicyclic amines, ammonia, and primary amines, and combinations thereof; buffers including sodium acetate and/or ammonium formate; precursors of ionic liquids including imidazoles; and combinations thereof.
  • bases including alkali metal and alkaline earth metal hydroxides, alkali metal and alkaline earth metal oxides, alkali metal and alkaline earth metal hydrides, alkali metal amides, alkali
  • the HCI scavenger comprises at least one base.
  • the base is selected from alkali metal and alkaline earth metal hydroxides, in particular from the group consisting of LiOH , NaOH , KOH , and Ca(OH)2.
  • the base is NaOH.
  • the base is selected from alkali metal and alkaline earth metal oxides, in particular from U2O, Na20, CaO, and MgO.
  • the base is selected from alkali metal and alkaline earth metal hydrides, in particular from LiH, NaH, KH, and CaH2.
  • the base is selected from alkali metal amides, in particular from the group consisting of L1NH2, NaNH2, and KNH2.
  • the base is selected from alkali metal and alkaline earth metal carbonates, in particular from K2CO3, U2CO3 and CaCC"3.
  • the base is selected from alkali metal bicarbonates, and is preferably NaHCC"3.
  • the base is selected from alkali metal alkyls, in particular from the group consisting of CH3L1, butyllithium, and phenyl- lithium.
  • the base is selected from alkylmagnesium halides, and is preferably CHsMgCI.
  • the base is selected from alkali metal and alkaline earth metal alcoholates, in particular from sodium methanolate, sodium ethanolate, potassium ethanolate, potassium tert-butanolate, and dimethoxymagnesi- um.
  • the base is a tertiary amine, in particular (CH3)3N,
  • the base is (CH3CH2)3N.
  • the base is a pyridine including substituted pyridines such as collidine, lutidine and 4-dimethylaminopyridine.
  • the base is a bicyclic amine.
  • the base is NH3.
  • the base is a primary amine, in particular CH3CH2NH2.
  • the base is (CHsCH2)3N or NaOH.
  • the HCI scavenger comprises at least one buffer.
  • the buffer is anhydrous sodium acetate or anhydrous ammonium formate.
  • the HCI scavenger comprises a precursor of an ionic liquid.
  • HCI scavengers are also possible, preferably a mix- tures of organic and inorganic bases, more preferably a mixture of alkali or earth metal carbonates and amines, more preferably a mixture of alkali carbonates and tertiary amines, e.g. a mixture of K2CO3 and (CHsCH2)3N.
  • the ratio of the inorganic base to the organic base may be from 10:1 to 1 :10, preferably from 5:1 to 1 :5, more preferably from 2:1 to 1 :2, and in particular 1.5:1 to 1 :1.5.
  • the (a) compounds IVa, their salts, tautomers, or enantiomers, or (b) compounds IVb, their salts, tautomers, or enantiomers, or a mixture of (a) and (b) may be produced in Process D by reaction of 3,4,5-trichloropyridazine with R 1 -NH2.
  • the 3,4,5-trichloropyridazine may in this case be produced in a separate production process by reaction of compounds V with POC .
  • the conditions for the reaction of compounds V with POCI3 are usually as follows. Typically, POCI3 is used in an excess. It has been discovered that the yield of Processes C and D can be increased by increasing the molar ratio of POCI3 to compounds V in the first reaction step.
  • the molar ratio of POCI3 to compounds V may be from 1 :1 to 20:1 , preferably from 3:1 to 15:1 , more preferably from 5:1 to 10:1.
  • the molar ratio of POCL3 to compounds V may be at least 2:1 , preferably at least 6:1. In one embodiment, the molar ratio of POCI3 to compounds V is approximately 7:1 , e.g. from 6.5:1 to 7.5:1.
  • POCI3 is used in an amount of at least 1 .5 mol per mol of the compound of formula V. In another embodiment, POCI3 is used in an amount of from 1 .5 to 2.0 mol per mol of the compound of formula II. In another embodiment,
  • POCI3 is used in an amount of from 2.0 to 10 mol per mol of the compound of formula II, preferably in an amount of from 4.0 to 6.0 mol, in particular in an amount of from 4.8 to 5.2 mol per mol of the compound of formula II.
  • POCI3 is used as a solvent.
  • the reaction is performed in the absence of a solvent differ- ent from POCI 3 .
  • suitable solvents are non-protic solvents, such as aliphatic hydrocarbons, preferably an aliphatic C5-Ci6-hydrocarbon, more preferably a C5-C16- alkane, or C5-Ci6-cycloalkane, such as pentane, hexane, cyclohexane, or petrol ether; aromatic hydrocarbons, preferably an aromatic C6-Cio-hydrocarbons, such as benzene, toluene, 0-, m-, and p-xylene; halogenated hydrocarbons, preferably halogenated aliphatic Ci-C6-alkanes, or halogenated aromatic C6-Cio-hydrocarbons, such as CH2CI2, CHCI3, CCU, CH2CICH2CI, CCI3CH3, CHCI2CH2CI, CCI2CCI2, or chlorobenzene; ethers, preferably Ci-C6-cycloal
  • the reaction is performed in a protective gas atmosphere, e.g. under N2.
  • the reaction temperature may be in the range of from 60 °C to 130 °C, preferably in the range of from 90 °C to 1 10 °C.
  • the reaction times may vary over a broad range, and are preferably in a range of from 0.5 hour to 24 hours, preferably in the range of from 0.5 hour to 5 hours, more preferably in the range of from 0.5 hour to 1.5 hours.
  • the excess POCI3 may be removed under reduced pressure.
  • H2O is preferably added to the reaction mixture upon cooling so that the tem- perature preferably does not exceed 30 °C.
  • the 3,4,5-trichloropyridazine can be isolated as a precipitate from the aqueous phase, or by transferring the 3,4,5-trichloropyridazine into an organic phase, and removing the organic solvent.
  • Preferred organic solvents in this connection include CH2CI2, CH3CH(CH3)CH 2 OH, CH3C(0)OCH 2 CH3, and CH 3 C(0)0(CH 2 )3CH 3 , in particular CH 3 C(0)0(CH 2 )3CH 3 .
  • the step of isolating the 3,4,5-trichloropyridazine can be omitted. Instead, the 3,4,5-trichloropyridazine is transferred to an organic phase and directly used in the next reaction step.
  • the organic phase may optionally be washed with a NaOH solution in H2O (e.g. a 10 % NaOH aqueous solution) and/or H2O prior to further use.
  • the amine compounds R 1 -NH2 may be in gaseous or liquid or solid form. If the amine compound R 1 -NH2 is in gaseous form, it may either be provided as a solution or as a gas.
  • a particularly preferred amine compound is CH3CH2NH2 as already indicated above.
  • Suitable solvents for the amine compounds R 1 -NH2 include protic solvents, preferably H2O, or Ci-C4-alcohols such as CH3OH, CH3CH2OH, CH3CH2CH2OH, CH 3 CH(OH)CH 3 , CH3CH2CH2CH2OH, and (CH 3 ) 3 COH, especially CH3CH2OH.
  • the solvent, wherein the amine compounds R 1 -NH2 is provided is H2O. In one preferred embodiment, the solvent, wherein the amine compounds R 1 -NH2 is provided, is CH3OH. Suitable concentrations of the amine compounds R 1 -NH2 in the solvent are in the range of from 10 to 100 wt% based on the total weight of the solution, preferably in the range of from 40 to 90 wt%, more preferably 60 to 80%, most preferably 66 to 72 wt%.
  • the amine compound R 1 -NH2 is CH3CH2NH2 and is provided as a solution in H2O with a concentration in the range of from 60 to 80% based on the total weight of the solution, preferably 66 to 72 wt%.
  • the amine compound R 1 -NH2 is provided in gaseous form and is introduced into the reaction mixture by bubbling it into the solvent, wherein the production of the dichloropyridazine amine compounds shall be performed, and wherein 3,4,5-trichloropyridazine may already be dissolved.
  • preferred sol- vents in which 3,4,5-trichloropyridazine may be added to the reaction mixture include protic solvents, preferably alcohols selected from the group consisting of CH3OH, CH3CH2OH, CH3CH2CH2OH, CH 3 CH(OH)CH 3 , CH 3 (CH 2 ) 3 OH, and C(CH 3 ) 3 OH.
  • preferred solvents, wherein the gaseous amine compound R 1 -NH2 may be dissolved for production of dichloropyrida- zine amine compounds generally include toluene, THF, and CH 3 CH20H.
  • an excess of the amine compound R 1 -NH2 is used compared with the amount of 3,4,5-trichloropyridazine.
  • the amine compound R 1 -NH2 is used in an amount of from 1 .5 to 10 mol per mol of 3,4,5-trichloropyridazine, preferably in an amount of from 2.0 to 6.0 mol, in particular in an amount of from 2.0 to 3.0 mol per mol of 3,4,5-trichloropyridazine.
  • Suitable solvents for the reaction of 3,4,5-trichloropyridazine with R 1 -NH2 include H2O; aliphatic hydrocarbons, preferably an aliphatic C5-Ci6-hydrocarbon, more preferably a C5-Ci6-alkane, or C5-Ci6-cycloalkane, such as pentane, hexane, cyclohexane, or petrol ether; aromatic hydrocarbons, preferably an aromatic C6-Cio-hydrocarbons, such as benzene, toluene, 0-, m-, and p-xylene; halogenated hydrocarbons, preferably halo- genated aliphatic Ci-C6-alkanes, or halogenated aromatic C6-Cio-hydrocarbons, such as CH2CI2, CHCIs, CCI4, CH2CICH2CI, CCI3CH3, CHCI2CH2CI, CCI2CCI2, or chloro
  • alcohols preferably Ci-C4-alcohols and C 2 -C 4 -alkane diols, such as CH3OH, CH3CH2OH, CH3CH2CH2OH, CH 3 CH(OH)CH 3 , CH 3 (CH 2 ) 3 OH, and C(CH 3 ) 3 OH, CH 2 (OH)CH 2 (OH), CH 3 CH(OH)CH 2 OH; esters, preferably esters of alipha- tic Ci-C6-alcohols with aliphatic Ci-C6-carboxylic acids, esters of aromatic C6-Cio-alco- hols with aromatic C6-Cio-carboxylic acids, cyclic esters of (jo-hydroxy-Ci-C6-carboxylic acids, such as CH 3 C(0)OCH
  • the reaction is performed in a mixture of the solvents, in which the starting materials are provided, e.g. a mixture of H2O and CH3C(0)0(CH2)3CH3.
  • the reaction is performed in protic solvents, preferably CH 3 OH, CH3CH2OH, CH 3 CH 2 CH 2 OH, CH 3 CH(OH)CH 3 ,
  • the reaction is performed in CH3OH.
  • the production of the dichloropyridazine amine may be performed in this protic solvent, and, optionally, also the subsequent reaction of the dichloropyridazine amine with H2 in the presence of a hydrogenation catalyst may be directly performed afterwards in a one-pot reaction.
  • the reaction may be carried out at temperatures in the range of from 0 to 140 °C, preferably from 25 °C to 60 °C, more preferably from 30 to 50 °C.
  • the reaction is performed at a temperature of 100 °C or less. In another embodiment, the reaction is carried out at a temperature of 80 °C or less. In another embodiment, the reaction is carried out at a temperature of 70 °C or less. In another embodiment, the reaction is carried out at a temperature of 60 °C or less. In one embodiment, the reaction is carried out at a temperature of from 0 to 100 °C. In another embodiment, the reaction is carried out at a temperature of from 0 to 80 °C. In another embodiment, the reaction is carried out at a temperature of from 0 to 70 °C.
  • the reaction is carried out at a temperature of from 0 to 60 °C. In another embodiment, the reaction is carried out t a temperature of from 20 to 80 °C. In another embodiment, the reaction is carried out a temperature of from 20 to 70 °C. In another embodiment, the reaction is carried out at a temperature of from 20 to 60 °C. In another embodiment, the reaction is carried out at a temperature of from 35 to 60 °C.
  • the reaction times may range from 1 hour to 4 days.
  • the reaction time is in the range of from 1 hour to 24 hours, in particular from 1 hour to 12 hours. More preferably, the reaction time is in the range of from 1 hour to 5 hours, preferably from 2 hours to 4 hours.
  • the reactants are preferably provided in similar amounts, e.g. in a molar ratio of from 1 .5:1 to 1 :1.5, preferably in equimolar amounts.
  • N2H4 is preferably provided in the form of a salt, preferably as hydrazine sulfate.
  • Suitable solvents include protic solvents such as H2O.
  • the reaction mixture is preferably heated to 100°C, until a precipitate forms.
  • US 4,728,355 e.g. Example 5
  • Mucochloric acid is commercially available.
  • Compounds IVa, and compounds IVb, their salts, tautomers, and enantiomers are ob- tainable by a process as described in PCT/EP2016/060461.
  • Compounds II, their salts, tautomers, and enantiomers are obtainable by a process as described in WO2010/034737.
  • WO2010/034737 specifically discloses the preparation of compounds II (cf. Example 1 ), wherein X is CI.
  • Compounds I, wherein X is not CI can be prepared from these acid chlorides by standard methods of organic chemistry. If individual compounds I cannot be obtained by the routes described above, they can be prepared by derivatization of other compounds I.
  • R 1 is H, Ci-C2-alkyl, or Ci-C2-alkoxy-Ci-C2-alkyl.
  • R 1 is CH 3 , CH2CH3, or CH2OCH3, preferably CH2CH3.
  • X is halogen, N3, p-nitrophenoxy, (2,5-dioxopyrrolidin-1 -yl)oxy, pentafluoro- phenoxy, OH, Ci-C6-alkoxy, C6-Cio-aryloxy, or C6-Cio-aryl-Ci-C6-alkoxy.
  • X is OH, Ci-C6-alkoxy, C6-Cio-aryloxy, or C6-Cio-aryl-Ci-C6-alkoxy.
  • X is OH.
  • X is Ci-C6-alkoxy, C6-Cio-aryloxy, or C6- Cio-aryl-Ci-C6-alkoxy. In another embodiment, X is halogen. In another embodiment, X is CI.
  • R 2 Ci-C 4 -alkyl, or Ci-C 4 -haloalkyl
  • R 4 Ci-C 4 -alkyl which is unsubstituted, halogenated, or is substituted with 1 , or
  • R x is CN or C(0)NH 2 ;
  • C3-C6-cycloalkyl which is unsubstituted, or substituted with 1 , 2, or 3 R y , wherein R y is halogen, CN, or C(0)NH 2 ;
  • R 5 Ci-C 4 -alkyl, which is unsubstituted, halogenated, or substituted with 1 , or 2 R x , wherein R x is CN, or C(0)NH 2 ; or
  • R 4 and R 5 together with the carbon atom to which they are attached form a 3- to
  • R 2 Ci-C 4 -alkyl, or Ci-C 4 -haloalkyl
  • R 4 Ci-C 4 -alkyl which is unsubstituted, halogenated, or is substituted with 1 , or 2 R x , wherein R x is selected from CN and C(0)NH 2 ; or
  • C3-C6-cycloalkyl which is unsubstituted, or substituted with 1 , 2, or 3 R y , wherein R y is halogen, CN, or C(0)NH 2 ;
  • R 5 Ci-C4-alkyl, which is unsubstituted, halogenated, or substituted with 1 , or 2 R x , wherein R x is CN, or C(0)NH 2 ; or
  • R 4 and R 5 together with the carbon atom to which they are attached form a 3- to 12-membered non-aromatic, saturated carbocycle, which is unsubstituted or substituted with Ri, wherein Ri is halogen, CN, or C(0)NH 2 ;
  • R N is CR 4 R 5 R 6 , R 2 is CH 3 , R 3 is H, R 6 is H; and wherein a) R 4 is CH 3 , R 5 is CH 3 ;
  • R 4 is CF 3 , R 5 is CH 3 ;
  • R 4 is CH(CH 3 ) 2 , R 5 is CH 3 ;
  • R 4 is CHFCH 3
  • R 5 is CH 3 ;
  • R 4 is 1 -CN-cC 3 H 4 , R 5 is CH 3 ;
  • R 4 is 1 -C(0)NH 2 -cC 3 H 4 , R 5 is CH 3 ; or
  • R 4 and R 5 together are CH 2 CH 2 CF 2 CH 2 CH 2 .
  • R N is CR 4 R 5 R 6 , R 2 is CH 3 , R 3 is H, R 6 is H; and wherein a) R 4 is CH 3 , R 5 is CH 3 ;
  • R 4 is CF 3 , R 5 is CH 3 ;
  • R 4 is CH(CH 3 ) 2 , R 5 is CH 3 ;
  • R 4 is CHFCHs, R 5 is CH 3 ;
  • R 4 is 1 -CN-cC 3 H 4 , R 5 is CH 3 ;
  • R 4 is 1 -C(0)NH 2 -cC 3 H 4 , R 5 is CH 3 ; or
  • R 4 and R 5 together are CH 2 CH 2 CF 2 CH 2 CH 2 ;
  • X is a CI.
  • a combination of bases as the HCI scavenger in Process B and/or as base in Process A is used.
  • an inorganic base preferably an alkali metal or alkaline earth metal carbonate, more preferably alkali metal carbonate, and in particular K 2 C0 3
  • an organic base preferably a tertiary amine, more preferably (CH 3 CH 2 ) 3 N
  • an inorganic base preferably an alkali metal or alkaline earth metal hydroxide, more preferably alkali metal hydroxide, and in particular NaOH
  • HCI scavenger preferably an alkali metal or alkaline earth metal hydroxide, more preferably alkali metal hydroxide, and in particular NaOH
  • organic base preferably a tertiary amine, more preferably (CH 3 CH 2 ) 3 N
  • an inorganic base preferably an alkali metal or alkaline earth metal hydroxide or carbonate, more preferably alkali metal hydroxide or carbonate, and in particular NaOH and K2CO3
  • HCI scavenger preferably an alkali metal or alkaline earth metal hydroxide or carbonate, more preferably alkali metal hydroxide or carbonate, and in particular NaOH and K2CO3
  • organic base preferably a tertiary amine, more preferably (CHsCH2)3N
  • an inorganic base preferably an alkali metal or alkaline earth metal carbonate, more preferably alkali metal carbonate, and in particular K2CO3
  • an organic base preferably a tertiary amine, more preferably (CHsCH2)3N
  • HCI scavenger is used as HCI scavenger in Process B.
  • the ratio of the equivalents of inorganic to organic bases in the above embodiments may be 1 :1 .
  • the ratio of equivalents of the inorganic to the organic base is at least 2:1 , preferably at least 3:1.
  • the ratio of equivalents of the inorganic to the organic bases is at least 1 :2, preferably at least 1 :3.
  • Process B and Process A are subsequently carried out as one- pot processes, wherein the product of Process B, compounds III, are not isolated prior to being used in Process A.
  • Process B and Process A are subsequently carried out as one-pot processes, wherein the product of Process B, compounds III, are not isolated prior to being used in Process A and are in the form of their HCI adduct salts, wherein no HCI scavenger, or a sub-equivalent amount of HCI scavenger compared to the produced HCI in the hydrogenation reaction is added after the removal of the hydrogena- tion catalyst in Process B.
  • Process B and Process A are subsequently carried out as one-pot processes, wherein the product of Process B, compounds III, are not isolated prior to being used in Process A, wherein an HCI scavenger is added in an at least equivalent amount compared to the amount of produced HCI in the hydrogenation reaction after the removal of the hydrogenation catalyst in Process B.
  • Process B and Process A are subsequently carried out as one-pot processes, wherein the product of Process B, compounds III, are not isolated prior to being used in Process A and are in the form of their HCI adduct salts, wherein no HCI scavenger, or a sub-equivalent amount of HCI scavenger compared to the produced HCI in the hydrogenation reaction is added after the removal of the hydrogenation catalyst in Process B, and wherein no HCI scavenger is present during the hydrogenation reaction in Process B.
  • Process B and Process A are subsequently carried out as one-pot processes, wherein the product of Process B, compounds III, are not isolated prior to being used in Process A, wherein an HCI scavenger is added in an at least equivalent amount compared to the amount of produced HCI in the hydrogenation reaction after the removal of the hydrogenation catalyst in Process B, and wherein no HCI scavenger is present during the hydrogenation reaction in Process B.
  • Process B and Process A are subsequently carried out as one-pot processes, wherein the product of Process B, compounds III, are not isolated prior to being used in Process A and are in the form of their HCI adduct salts, wherein a sub-equivalent amount of HCI scavenger compared to the produced HCI in the hydrogenation reaction is added after the removal of the hydrogenation catalyst in Process B, and wherein no HCI scavenger is present during the hydrogenation reaction in Process B.
  • Process B and Process A are subsequently carried out as one-pot processes, wherein the product of Process B, compounds III, are not isolated prior to being used in Process A and are in the form of their HCI adduct salts, wherein no HCI scavenger, or a sub-equivalent amount of HCI scavenger compared to the produced HCI in the hydrogenation reaction is added after the removal of the hydrogena- tion catalyst in Process B, wherein no HCI scavenger is present during the hydrogenation reaction in Process B, and wherein the solvent in Process B is CH3OH.
  • Process B and Process A are subsequently carried out as one-pot processes, wherein the product of Process B, compounds III, are not isolated prior to being used in Process A, wherein an HCI scavenger is added in an at least equivalent amount compared to the amount of produced HCI in the hydrogenation reaction after the removal of the hydrogenation catalyst in Process B, wherein no HCI scavenger is present during the hydrogenation reaction in Process B, and wherein the solvent in Process B is CH3OH.
  • Process B and Process A are subsequently carried out as one-pot processes, wherein the product of Process B, compounds III, are not isolated prior to being used in Process A and are in the form of their HCI adduct salts, wherein a sub-equivalent amount of HCI scavenger compared to the produced HCI in the hydrogenation reaction is added after the removal of the hydrogenation catalyst in Process B, and wherein no HCI scavenger is present during the hydrogenation reaction in Process B, and wherein the solvent in Process B is CH3OH.
  • Process B and Process A are subsequently carried out as one-pot processes, wherein the product of Process B, compounds III, are not isolated prior to being used in Process A and are in the form of their HCI adduct salts, wherein no HCI scavenger, or a sub-equivalent amount of HCI scavenger compared to the pro- Jerusalem HCI in the hydrogenation reaction is added after the removal of the hydrogenation catalyst in Process B, wherein no HCI scavenger is present during the hydrogenation reaction in Process B, and wherein the solvent in Processes A and B is CH3OH.
  • Process B and Process A are subsequently carried out as one-pot processes, wherein the product of Process B, compounds III, are not isolated prior to being used in Process A, wherein an HCI scavenger is added in an at least equivalent amount compared to the amount of produced HCI in the hydrogenation reaction after the removal of the hydrogenation catalyst in Process B, wherein no HCI scavenger is present during the hydrogenation reaction in Process B, and wherein the solvent in Processes A and B is CH3OH.
  • Process B and Process A are subsequently carried out as one-pot processes, wherein the product of Process B, compounds III, are not isolated prior to being used in Process A and are in the form of their HCI adduct salts, wherein a sub-equivalent amount of HCI scavenger compared to the produced HCI in the hy- drogenation reaction is added after the removal of the hydrogenation catalyst in Process B, and wherein no HCI scavenger is present during the hydrogenation reaction in Process B, and wherein the solvent in Processes A and B is CH3OH.
  • Process B and Process A are subsequently carried out as one-pot processes, wherein the product of Process B, compounds III, are not isolated prior to being used in Process A and are in the form of their HCI adduct salts, wherein no HCI scavenger, or a sub-equivalent amount of HCI scavenger compared to the produced HCI in the hydrogenation reaction is added after the removal of the hydrogenation catalyst in Process B, wherein no HCI scavenger is present during the hydrogena- tion reaction in Process B, and wherein the solvent in Process B is CH3CH2OH.
  • Process B and Process A are subsequently carried out as one-pot processes, wherein the product of Process B, compounds III, are not isolated prior to being used in Process A, wherein an HCI scavenger is added in an at least equivalent amount compared to the amount of produced HCI in the hydrogenation re- action after the removal of the hydrogenation catalyst in Process B, wherein no HCI scavenger is present during the hydrogenation reaction in Process B, and wherein the solvent in Process B is CH3CH2OH.
  • Process B and Process A are subsequently carried out as one-pot processes, wherein the product of Process B, compounds III, are not isolated prior to being used in Process A and are in the form of their HCI adduct salts, wherein a sub-equivalent amount of HCI scavenger compared to the produced HCI in the hydrogenation reaction is added after the removal of the hydrogenation catalyst in Process B, and wherein no HCI scavenger is present during the hydrogenation reaction in Process B, and wherein the solvent in Process B is CH3CH2OH.
  • a one-pot production process comprising Processes B followed by Process A, as defined above, wherein compounds III are not isolated before being used in Process A.
  • HCI scavenger is an inorganic base, preferably an alkali or alkaline earth metal carbonate, in particular K2CO3, or an alkali or alkaline earth metal hydroxide, in particular NaOH.
  • the HCI scavenger is a mixture of an inorganic base and an organic base, preferably a mixture of an alkali or alkaline earth meatal carbonate and an amine base, in particular a mixture of (CH 3 CH 2 ) 3 N and K2CO3.
  • HPLC High Performance Liquid Chromatography
  • composition was then filtrated through silica gel to yield a solution of the HCI adduct of N-ethylpyridazin-4-amine (compound 111.1 ) in CH3CH2OH at a concentration of 6.6 wt% based on the total mass of the solution.
  • To 222 g of the solution containing compound III.1 was added 18.54 g of (CH3CH2)3N in a reaction vessel at 20 to 25 °C under stirring over period of 25 min.
  • a composition containing 39.6 g of a mixture containing compound IVa.1 and compound IVb.1 , 100 g CH3OH, and 5.3 g of a Pd/C catalyst (5 wt% Pd of the total mass of the catalyst) was added to a pressure reactor. Subsequently, the composition was stirred and Fb-gas was introduced into the pressure reactor to a final pressure of 6 bar that was maintained at 65 °C for 4.5 h. The composition was then stirred overnight at 4 bar Fb-gas pressure. The composition was then filtrated through silica gel to yield a solution of the HCI adduct of compound III.1 in CH3OH.
  • CH3OH was removed by evaporation under reduced pressure.
  • the removed CH3OH was replaced stepwise with toluene to maintain the concentration of all reactants in the solvent.
  • the evaporation process was carried out until the amount of CH3OH detectable by gas chromatography was reduced to a concentration of lower than 500 ppm.
  • a composition containing 97.5 g of a mixture containing compounds (IVa.1 ) and compounds (IVb.1 ), 224 g CH 3 OH and 13.2 g of a Pd/C catalyst (2 wt% Pd of the total mass of the catalyst) was added to a pressure reactor. Subsequently, the composition was stirred and hb-gas was introduced into the pressure reactor to a final pressure of 6.1 bar that was maintained at 65 °C for 6 h. The composition was then stirred overnight at 3 bar hb-gas pressure without heating.
  • composition was then filtrated to yield a solution of the HCI adduct of compound III.1 in CH3OH at a concentration of 16.6 wt% based on the total mass of the solution, corresponding to a yield of 94%.
  • the solid catalyst was washed in a Buchner fun- nel.
  • CH3OH was removed by distillation.
  • the removed CH3OH was replaced stepwise with toluene to maintain the concentration of all reactants in the solvent.
  • the distillation process was carried until a boiling temperature of 1 10 °C was reached, marking the completion of the solvent swap from CH3OH to toluene when a total of 236.2 g of distillate had been collected.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne un procédé de production des composés (I), leurs sels, tautomères ou énantiomères ; par la réaction de composés (II), leurs sels, tautomères ou énantiomères ; avec des composés (III), leurs sels, tautomères, ou énantiomères et des composés III sous la forme de leurs produits d'addition HCl.
PCT/EP2017/077091 2016-11-04 2017-10-24 Procédé de production de pyridazinyle-amides dans une synthèse one pot WO2018082964A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16197196 2016-11-04
EP16197196.5 2016-11-04

Publications (1)

Publication Number Publication Date
WO2018082964A1 true WO2018082964A1 (fr) 2018-05-11

Family

ID=57226865

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/077091 WO2018082964A1 (fr) 2016-11-04 2017-10-24 Procédé de production de pyridazinyle-amides dans une synthèse one pot

Country Status (1)

Country Link
WO (1) WO2018082964A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10961213B2 (en) 2017-01-25 2021-03-30 Basf Se Process for preparation of benzylic amides
US10961226B2 (en) 2016-11-04 2021-03-30 Basf Se Process for purification of pyrazolpyridazines
CN113272296A (zh) * 2019-01-11 2021-08-17 巴斯夫欧洲公司 1-(1,2-二甲基丙基)-n-乙基-5-甲基-n-哒嗪-4-基-吡唑-4-甲酰胺的结晶形式
US11261145B2 (en) 2017-03-20 2022-03-01 Basf Se Process for preparing bromotrichloromethane
US11284619B2 (en) 2017-02-14 2022-03-29 Basf Se Stable formulation of pesticidal pyridazinpyrazolamides
US11358922B2 (en) 2017-11-02 2022-06-14 Basf Se Process for preparing 4-chlorobenzyl propargyl ether
WO2024079733A1 (fr) 2022-10-12 2024-04-18 Adama Makhteshim Ltd. Procédé de préparation de dérivés d'aminopyridazine

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4728355A (en) 1985-10-10 1988-03-01 Fmc Corporation Pyridazinylurea plant regulators
WO1996018628A1 (fr) 1994-12-13 1996-06-20 Pharmacia & Upjohn Company Composes de piperadinyle et piperazinyle anti-sida a substitution alkyle
WO1999064402A1 (fr) 1998-06-05 1999-12-16 EGIS Gyógyszergyár Rt. Procede de preparation d'un derive amino-5-chloro 3(2h)-pyridazinone-4-substitue
WO2001007436A2 (fr) 1999-07-28 2001-02-01 Aventis Pharmaceuticals Inc. Composes d'oxoazaheterocyclyle substitue
US6258822B1 (en) 1997-08-06 2001-07-10 Abbott Laboratories Urokinase inhibitors
WO2002100352A2 (fr) 2001-06-12 2002-12-19 Merck & Co., Inc. Antagonistes du recepteur nr2b pour le traitement ou la prevention de migraines
WO2009152325A1 (fr) 2008-06-12 2009-12-17 Janssen Pharmaceutica Nv Modulateurs de diamino-pyridine, pyrimidine et pyridazine du récepteur de l'histamine h<sb>4</sb>
WO2010034738A2 (fr) 2008-09-24 2010-04-01 Basf Se Composés pyrazoliques utilisables dans la lutte contre les invertébrés nuisibles
WO2010034737A1 (fr) 2008-09-24 2010-04-01 Basf Se Composés de pyrazole pour la lutte contre des parasites invertébrés
WO2010049841A1 (fr) 2008-10-30 2010-05-06 Pfizer Inc. Composés 7-azaspiro[3.5]nonane-7-carboxamide comme modulateurs de l’hydrolase d’amides d’acides gras
WO2010112177A1 (fr) 2009-04-03 2010-10-07 Bayer Cropscience Aktiengesellschaft Amines pyridines et –pyridazines acylées en tant qu'insecticides
WO2011038572A1 (fr) 2009-09-29 2011-04-07 Glaxo Group Limited Composés inédits
WO2011124524A1 (fr) 2010-04-08 2011-10-13 Boehringer Ingelheim International Gmbh Combinaisons de produits pharmaceutiques contenant des inhibiteurs de pde4 et des antagonistes du récepteur ep4
WO2012098387A1 (fr) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Dérivés de triazolo[4,3-b]pyridazines au cycle 6,7 fusionné utilisés en tant qu'inhibiteurs de pim
WO2013004984A1 (fr) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncologicas (Cnio) Composés tricycliques pour l'utilisation en tant qu'inhibiteurs de kinase
WO2013142269A1 (fr) 2012-03-19 2013-09-26 Envivo Pharmaceuticals, Inc. Composés d'imidazotriazinone
WO2014091368A1 (fr) 2012-12-14 2014-06-19 Pfizer Limited Dérivés d'imidazopyridazine en tant que modulateurs d'un récepteur gabaa
WO2015055497A1 (fr) * 2013-10-16 2015-04-23 Basf Se Composés pesticides de pyrazole substitué
WO2016012958A1 (fr) * 2014-07-23 2016-01-28 Aurigene Discovery Technologies Limited Dérivés de 4,5-dihydroisoxazole comme inhibiteurs de nampt
WO2016180833A1 (fr) 2015-05-11 2016-11-17 Basf Se Procédé de préparation de 4-amino-pyridazines

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4728355A (en) 1985-10-10 1988-03-01 Fmc Corporation Pyridazinylurea plant regulators
WO1996018628A1 (fr) 1994-12-13 1996-06-20 Pharmacia & Upjohn Company Composes de piperadinyle et piperazinyle anti-sida a substitution alkyle
US6258822B1 (en) 1997-08-06 2001-07-10 Abbott Laboratories Urokinase inhibitors
WO1999064402A1 (fr) 1998-06-05 1999-12-16 EGIS Gyógyszergyár Rt. Procede de preparation d'un derive amino-5-chloro 3(2h)-pyridazinone-4-substitue
WO2001007436A2 (fr) 1999-07-28 2001-02-01 Aventis Pharmaceuticals Inc. Composes d'oxoazaheterocyclyle substitue
WO2002100352A2 (fr) 2001-06-12 2002-12-19 Merck & Co., Inc. Antagonistes du recepteur nr2b pour le traitement ou la prevention de migraines
WO2009152325A1 (fr) 2008-06-12 2009-12-17 Janssen Pharmaceutica Nv Modulateurs de diamino-pyridine, pyrimidine et pyridazine du récepteur de l'histamine h<sb>4</sb>
WO2010034738A2 (fr) 2008-09-24 2010-04-01 Basf Se Composés pyrazoliques utilisables dans la lutte contre les invertébrés nuisibles
WO2010034737A1 (fr) 2008-09-24 2010-04-01 Basf Se Composés de pyrazole pour la lutte contre des parasites invertébrés
WO2010049841A1 (fr) 2008-10-30 2010-05-06 Pfizer Inc. Composés 7-azaspiro[3.5]nonane-7-carboxamide comme modulateurs de l’hydrolase d’amides d’acides gras
WO2010112177A1 (fr) 2009-04-03 2010-10-07 Bayer Cropscience Aktiengesellschaft Amines pyridines et –pyridazines acylées en tant qu'insecticides
WO2011038572A1 (fr) 2009-09-29 2011-04-07 Glaxo Group Limited Composés inédits
WO2011124524A1 (fr) 2010-04-08 2011-10-13 Boehringer Ingelheim International Gmbh Combinaisons de produits pharmaceutiques contenant des inhibiteurs de pde4 et des antagonistes du récepteur ep4
WO2012098387A1 (fr) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Dérivés de triazolo[4,3-b]pyridazines au cycle 6,7 fusionné utilisés en tant qu'inhibiteurs de pim
WO2013004984A1 (fr) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncologicas (Cnio) Composés tricycliques pour l'utilisation en tant qu'inhibiteurs de kinase
WO2013142269A1 (fr) 2012-03-19 2013-09-26 Envivo Pharmaceuticals, Inc. Composés d'imidazotriazinone
WO2014091368A1 (fr) 2012-12-14 2014-06-19 Pfizer Limited Dérivés d'imidazopyridazine en tant que modulateurs d'un récepteur gabaa
WO2015055497A1 (fr) * 2013-10-16 2015-04-23 Basf Se Composés pesticides de pyrazole substitué
WO2016012958A1 (fr) * 2014-07-23 2016-01-28 Aurigene Discovery Technologies Limited Dérivés de 4,5-dihydroisoxazole comme inhibiteurs de nampt
WO2016180833A1 (fr) 2015-05-11 2016-11-17 Basf Se Procédé de préparation de 4-amino-pyridazines

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DONNA L. ROMERO ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, no. 19, 1996, pages 3769 - 3789
F. CHANG ET AL., BULL. KOREAN CHEM. SOC., vol. 32, no. 3, 2011, pages 1075
JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 21, no. 5, 1984, pages 1389 - 92
JOURNAL OF ORGANOMETALLIC CHEMISTRY, vol. 370, 1989, pages 17 - 31
RUSSIAN JOURNAL OF APPLIED CHEMISTRY, vol. 77, no. 12, 2004, pages 1997 - 2000
TSUKASA KURAISHI ET AL., JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 1, 1964, pages 42 - 47
TSUKASA KURAISHI: "4, 5-Substituted Pyridazines. I.", PHARMACEUTICAL BULLETIN, vol. 4, no. 6, 1 January 1956 (1956-01-01), pages 497 - 499, XP055330300, ISSN: 0369-9471, DOI: 10.1248/cpb1953.4.497 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10961226B2 (en) 2016-11-04 2021-03-30 Basf Se Process for purification of pyrazolpyridazines
US10961213B2 (en) 2017-01-25 2021-03-30 Basf Se Process for preparation of benzylic amides
US11284619B2 (en) 2017-02-14 2022-03-29 Basf Se Stable formulation of pesticidal pyridazinpyrazolamides
US11261145B2 (en) 2017-03-20 2022-03-01 Basf Se Process for preparing bromotrichloromethane
US11358922B2 (en) 2017-11-02 2022-06-14 Basf Se Process for preparing 4-chlorobenzyl propargyl ether
CN113272296A (zh) * 2019-01-11 2021-08-17 巴斯夫欧洲公司 1-(1,2-二甲基丙基)-n-乙基-5-甲基-n-哒嗪-4-基-吡唑-4-甲酰胺的结晶形式
WO2024079733A1 (fr) 2022-10-12 2024-04-18 Adama Makhteshim Ltd. Procédé de préparation de dérivés d'aminopyridazine

Similar Documents

Publication Publication Date Title
US11046656B2 (en) Process for preparing 4-amino-pyridazines
WO2018082964A1 (fr) Procédé de production de pyridazinyle-amides dans une synthèse one pot
RU2733958C2 (ru) Способ каталитического гидрирования для получения пиразолов
KR102531217B1 (ko) 피라졸의 제조 방법
AU2024203203A1 (en) Process for preparing a Cot inhibitor compound
TWI530488B (zh) 泛－ｃｄｋ抑制劑之製備方法及中間體
JP7161275B2 (ja) ４－アミノ－ピリダジンを製造するための方法
RU2778306C1 (ru) Способ получения 4-аминопиридазинов
JP5516567B2 (ja) ４−アミノ−２−アルキルチオ−５−ピリミジンカルバルデヒドの製法
JP6922924B2 (ja) 含窒素化合物の製造方法
WO2021175959A1 (fr) Procédé de préparation de carboxylates et d&#39;amides d&#39;acide 5-chloro-3-alkylsulfanyl-pyridine-2-carboxylique
JP4792892B2 (ja) シアノケトンのアルカリ金属塩の製法
CA3019281A1 (fr) Nouveau procede de production d&#39;un derive d&#39;acide hydroxamique, et intermediaire correspondant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17784983

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17784983

Country of ref document: EP

Kind code of ref document: A1